3D011-08 Monotherapy in Subjects With Advanced Solid Tumors

Solid Tumor, Adult Clinical Trial

Official title:

A Phase I Study of the Safety, Tolerability, Pharmacokinetics Profiles and Preliminary Efficacy of 3D011-08 for Injection Monotherapy in Subjects With Advanced Solid Tumors

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05099536
• Other study ID #: 3D011-CN-001
• Status: Withdrawn
• Phase: Phase 1
• Start date: February 24, 2022
• Est. completion date: September 11, 2023

Study information

• Verified date: January 2024
• Source: 3D Medicines
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is evaluate the the safety, tolerability, pharmacokinetics profiles, and preliminary efficacy of 3D011-08 in subjects with advanced solid tumors.

Description:

Detailed Description: This study was initiated on February 24, 2022, at Fudan Cancer Hospital. However, noparticipants were screened or enrolled after the initiation. Due to strategic development adjustments, thecompany terminated the study on September 11. 2023.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 11, 2023
• Est. primary completion date: September 11, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically or cytologically confirmed locally advanced or metastatic malignant solid tumors(part 1 dose escalation); Histologically confirmed locally advanced or metastatic hepatocellular carcinoma (cohort 1),advanced renal cell carcinoma (cohort 2), and metastatic castration-resistant prostate cancer (cohort 3) for which not amenable to local therapy.(part 2 dose expansion).

2. Cohort 1 and 2: at least one measurable lesion (according to RECIST 1.1 criteria);Cohort 3: at least one measurable or unmeasurable lesion (according to RECIST 1.1 criteria).

3. Subjects must have failed or have been intolerant to established standard therapies, or standard therapies did not exist or were no longer effective for a given tumor type, or in the opinion of the Investigator have been considered ineligible for a particular form of standard therapy on medical grounds(part 1 dose escalation). Cohort 1 (advanced hepatocellular carcinoma)and Cohort 2 (advanced renal cell carcinoma): Subjects had disease progression after received previous first-line of systemic treatment, or subjects are intolerant of or have refused to receive first-line of systemic treatment. Cohort 3 (metastatic castration-resistant prostate cancer) : Patients who had failed or had refused prior abiraterone and/or docetaxel chemotherapy.(part 2 dose expansion)

4. ECOG Performance Status = 2(part 1 dose escalation).= 1.(part 2 dose expansion)

5. Life expectancy = 12 weeks.

6. Adequate organ and bone marrow function.

Exclusion Criteria:

1. Investigational products or devices in other clinical trials or received antibody drug therapy within 4 weeks before the first dose,or chemotherapy, targeted therapies,or radiotherapy within 2 weeks before the first dose.

2. Participants need to continue using medications known to have a significant risk of causing QTc prolongation or a CYP3A4 strong inhibitor or strong inducer.

3. Participants who have previous toxicity of anti-tumor therapy that has not been returned to level 0 or 1.

4. Participants with diseases at risk of bleeding within 3 months prior to enrollment

5. Participants with concomitant medical conditions requiring anticoagulant therapy at a therapeutic dose

6. History or current condition of uncontrolled cardiovascular disease.

7. Participants with gastrointestinal disease associated with a risk of perforation or fistula formation

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor, Adult

Intervention

Drug:
• 3D011-08
participants will receive 15mg (starting dose)intravenous drop of 3D011-08,All subjects in each cohort will receive a single dose of 3D011-08 first, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive doses on 1,3,5day of each week (28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first.Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RPTD).

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai	Floor 2, Building 2, 270 Dong 'an Road, Xuhui District

Sponsors (1)

Lead Sponsor	Collaborator
3D Medicines (Beijing) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD) of3D011-08	The maximum tolerated dose as determined in Part 1 of the study will be used as the recommended dose for Part 2.	24 months
Primary	ORR	proportion of subjects in cohort 1 and cohort 2 who achieved a confirmed complete response (CR) or partial response (PR) based on RECIST v1.1 as assessed by investigators.	24 Months
Primary	TTP	time to progression based on the PCWG3 recommendations for assessment of prostate cancer disease progression (CT/MRI, bone scan) as assessed by investigators .	24 Months
Secondary	RPTD	RP2D will be determined based on pharmacodynamics or clinical response, as well as the incidence rate and nature of the toxicities observed.	24 months
Secondary	Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)		24 months
Secondary	Cmax Cmax		24 months
Secondary	Css min		24 months
Secondary	Tmax		24 months
Secondary	AUC0~t?AUC0~8		24 months
Secondary	Ctrough		24 months
Secondary	t1/2		24 months
Secondary	CL		24 months
Secondary	Vd		24 months
Secondary	ORR	proportion of subjects in part of Dose Escalation who achieved a confirmed complete response (CR) or partial response (PR) based on RECIST v1.1 as assessed by investigators.proportion of subjects in dose expansion cohort 3 who achieved a confirmed complete response (CR) or partial response (PR) based on the PCWG3 recommendations for assessment of prostate cancer disease progression (CT/MRI, bone scan) as assessed by investigators .	24 months
Secondary	Duration of response (DoR)	DoR is defined as the time from the date of first CR or PR based on RECIST v1.1 to the date of first documented progressive disease based on RECIST v1.1 or death, whichever occurs first.part1 Dose Escalation,part 2 dose expansion:Cohort 1 and Cohort 2.	24 months
Secondary	Disease control rate (DCR)	defined as the proportion of subjects who achieve a confirmed complete response (CR) or partial response (PR) or stable disease (SD) based on RECIST v1.1 as assessed by investigators.Proportion of subjects in dose expansion cohort 3 who achieve a confirmed complete response (CR) or partial response (PR) or stable disease (SD) based on the PCWG3 recommendations for assessment of prostate cancer disease progression (CT/MRI, bone scan) as assessed by investigators .	24 months
Secondary	Progression-free survival (PFS)	PFS is defined as the time from the date of first study dose to disease progression based on RECIST v1.1 or death, whichever occurs first. Subjects in dose expansion cohort 3 based on the PCWG3 recommendations for assessment of prostate cancer disease progression (CT/MRI, bone scan) as assessed by investigators .	24 months
Secondary	Permeable surface area of capillary wall(PS)		24 months
Secondary	the incremental Area Under Curve (iAUC)		24 months